Key result
Amlodipine did not slow the 36-month angiographic progression of coronary atherosclerosis compared to placebo.
Why the study?
Does amlodipine slow the progression of early coronary atherosclerosis in patients with angiographically documented coronary artery disease?
RCT (n=825)
double-masked
randomized
Yes
Does amlodipine slow the progression of early coronary atherosclerosis in patients with angiographically documented coronary artery disease?
Amlodipine did not slow the angiographic progression of coronary atherosclerosis but significantly slowed carotid atherosclerosis progression and reduced hospitalizations for unstable angina and revascularization.
Answers are grounded in this paper and cite their sources.
Amlodipine does not slow angiographic coronary atherosclerosis progression; challenges prior calcium channel blocker data and does not support use for this indication.
BACKGROUND: The results of angiographic studies have suggested that calcium channel-blocking agents may prevent new coronary lesion formation, the progression of minimal lesions, or both. METHODS AND RESULTS: The Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) was a multicenter, randomized, placebo-controlled, double-masked clinical trial designed to test whether amlodipine would slow the progression of early coronary atherosclerosis in 825 patients with angiographically documented coronary artery disease. The primary outcome was the average 36-month angiographic change in mean minimal diameters of segments with a baseline diameter stenosis of 30%. A secondary hypothesis was whether amlodipine would reduce the rate of atherosclerosis in the carotid arteries as assessed with B-mode ultrasonography, which measured intimal-medial thicknesses (IMT). The rates of clinical events were also monitored. The placebo and amlodipine groups had nearly identical average 36-month reductions in the minimal diameter: 0.084 versus 0.095 mm, respectively (P:=0.38). In contrast, amlodipine had a significant effect in slowing the 36-month progression of carotid artery atherosclerosis: the placebo group experienced a 0.033-mm increase in IMT, whereas there was a 0. 0126-mm decrease in the amlodipine group (P:=0.007). There was no treatment difference in the rates of all-cause mortality or major cardiovascular events, although amlodipine use was associated with fewer cases of unstable angina and coronary revascularization. CONCLUSIONS: Amlodipine has no demonstrable effect on angiographic progression of coronary atherosclerosis or the risk of major cardiovascular events but is associated with fewer hospitalizations for unstable angina and revascularization.
No takes yet. Share an insight, caveat, or question.
Pitt et al. (2000) conducted an RCT in coronary artery disease (n=825). amlodipine vs. placebo was evaluated on average 36-month angiographic change in mean minimal diameters of segments with a baseline diameter stenosis of 30% (p=0.38). Amlodipine did not slow the 36-month angiographic progression of coronary atherosclerosis compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: